Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (Nasdaq: MRNA) has announced a new order commitment from the Canadian Government for an additional 4 million doses of its COVID-19 vaccine, bringing the total to 44 million doses. This increase highlights the Canadian Government's efforts to ensure vaccine availability for its citizens. Moderna's CEO, Stephane Bancel, expressed appreciation for this collaboration and emphasized the confidence in the vaccine's efficacy. Health Canada previously authorized the vaccine for individuals aged 18 and older, demonstrating continued regulatory support for Moderna's mRNA technology.
Moderna (Nasdaq: MRNA) announced the U.S. government's purchase of 100 million additional doses of its COVID-19 vaccine, totaling 300 million confirmed orders. With 41 million doses supplied to date, over 22 million Americans have received the vaccine. Moderna aims to deliver the first 100 million doses by Q1 2021 and the second by Q2 2021, leveraging its U.S. manufacturing capabilities. The company has secured agreements for over 631.5 million doses with various countries, reinforcing its role in the global fight against COVID-19.
Moderna, Inc. (Nasdaq: MRNA) announced that Qatar's Ministry of Public Health granted emergency use authorization for the COVID-19 Vaccine Moderna. This authorization is a significant milestone in the global fight against COVID-19, reflecting confidence in Moderna's mRNA vaccine. The approval is based on scientific evidence from a Phase 3 clinical study. The vaccine has already been authorized in multiple regions, including the U.S., EU, and UK. Moderna remains committed to working with global health agencies to expand its vaccine's availability.
Moderna, Inc. (Nasdaq: MRNA) announced supply agreements for its COVID-19 Vaccine Moderna with Taiwan (5 million doses) and Colombia (10 million doses). Deliveries are set to commence in mid-2021, pending regulatory approvals in both countries. The vaccine is based on mRNA technology and has received various authorizations globally. Moderna emphasizes collaboration with both governments in this effort.
Moderna (Nasdaq: MRNA) will host a live conference call on February 25, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. The call can be accessed by dialing 866-922-5184 domestically or 409-937-8950 internationally, with conference ID 4066945. Moderna has evolved significantly over the past ten years, moving from research-stage activities to commercial success, primarily recognized for its COVID-19 vaccine, now widely used. The company has 24 development programs, with 13 in clinical stages across various therapeutic areas.
Moderna, Inc. (Nasdaq: MRNA) has received interim authorization from the Singapore Health Sciences Authority for its mRNA COVID-19 vaccine under the Pandemic Special Access Route. This decision marks a significant milestone in the global COVID-19 response. The authorization is based on extensive scientific evidence, including data from its pivotal Phase 3 clinical trial. Moderna's vaccine is already approved in several countries, including the U.S., Canada, and the EU. The company continues to advance mRNA technology for various therapeutic areas, supported by strategic alliances with major pharmaceutical firms.
Moderna (Nasdaq: MRNA) announced an increase in its COVID-19 vaccine supply agreement with the Swiss Federal Government from 7.5 million to 13.5 million doses. This decision underscores the government's confidence in Moderna, with deliveries starting in summer 2021 and an option for additional doses in early 2022. The vaccine was authorized by Swissmedic, supporting Moderna's expansion strategy beyond North America. The company continues to enhance its mRNA vaccine platform, which has gained regulatory approval and shows promise in various therapeutic areas.
Moderna (Nasdaq: MRNA) is in discussions with the U.S. government for an additional 100 million doses of its COVID-19 vaccine, aiming for delivery in Q3 2021. This new agreement would increase the total doses to 300 million. Moderna leverages its U.S. manufacturing capacity to fulfill this order. The vaccine received Emergency Use Authorization from the FDA on December 18, 2020, and has been pivotal in the fight against the pandemic. However, the press release includes various safety considerations and potential risks associated with vaccine administration.
Moderna, Inc. (Nasdaq: MRNA) has supplied 30.4 million doses of its COVID-19 vaccine to the U.S. government, with 10.1 million administered in the country. The company is on track to deliver 100 million doses by the end of Q1 2021 and 200 million total by the end of Q2 2021. Moderna has increased its global production estimate for 2021 from 500 to 600 million doses, aiming for up to 1 billion doses. The vaccine has received Emergency Use Authorization from the FDA, and additional authorizations are pending in other countries.
Moderna, Inc. (Nasdaq: MRNA) announced a conference call on January 25 at 4:30 PM ET to discuss in vitro neutralization studies of its COVID-19 vaccine against emerging SARS-CoV-2 strains. The findings indicate that the vaccine retains neutralizing activity, a critical factor in ongoing pandemic response efforts. The call will also be accessible via a webcast. Over the past decade, Moderna has evolved significantly, demonstrating its mRNA technology's potential with multiple vaccines and therapies in development, enhancing its position in the biotechnology field.